Abstract: Disclosed are compositions comprising beta-caryophyllene (BCP) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using BCP. Disclosed are also compositions comprising CB2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using CB2 receptor agonists.

Abstract: Disclosed are compositions comprising beta-caryophyllene (BCP) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using BCP. Disclosed are also compositions comprising CB2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using CB2 receptor agonists.

Abstract: Disclosed are compositions comprising beta-caryophyllene (BCP) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using BCP. Disclosed are also compositions comprising CB2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using CB2 receptor agonists.

Abstract: The present invention provides a method of treatment of a neuropsychiatric disorder characterized by repetitive pheno-type, comprising administering to a human or non-human subject in need thereof a therapeutically effective dose of a pharmaceutical composition comprising at least one active agent selected from a group of active agents comprising CB2 receptor inverse agonists and mixed CB2/SERM ligands. The present invention further provides pharmaceutical compositions comprising 4?-0-methylhonokiol, raloxifene, and their derivatives, HU-308 and/or BCP.

Abstract: Aspects of the invention provide methods of screening for a mental disease selected from schizophrenia, psychosis and phencyclidine abuse and addiction in a subject or a subject population, diagnosing schizophrenia, psychosis and phencyclidine abuse and addiction in a subject by determining the magnitude of expression of at least one gene and providing tools for selection of a treatment and a list of therapeutic agents for the treatment of schizophrenia, psychosis and phencyclidine abuse or addiction based on said screening and diagnosis of a human or a nonhuman animal.

Abstract: Disclosed are stable compositions comprising at least one CB2 receptor selective or highly selective agonist and optionally at least one antipsychotic for use in the treatment of mental disorders, methods of preparing such compositions and methods of treating mental disorders using same. Disclosed are also compositions comprising beta caryophyllene (BCP) or HU-308 for use in the treatment of mental disorders one of which is schizophrenia, methods of making such compositions and methods of treating mental disorders one of which is schizophrenia.

Abstract: Disclosed are stable self-emulsifying compositions comprising at least one CB2 receptor modulator, a self-emulsifying vehicle and optionally at least one antipsychotic agent for use in the treatment of mental disorders, methods of preparing such compositions and methods of treating mental disorders using same. Disclosed are also stable self-emulsifying compositions comprising beta caryophyllene (BCP) or HO-308 as sole active agent or in combination with humulene, an antipsychotic for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia rising BCP.

Abstract: The present invention provides a method of treatment of a neuropsychiatric disorder characterized by repetitive phenotype, comprising administering to a human or non-human subject in need thereof a therapeutically effective dose of a pharmaceutical composition comprising at least one active agent selected from a group of active agents comprising CB2 receptor inverse agonists and mixed CB2/SERM ligands. The present invention further provides pharmaceutical compositions comprising 4?-0-methylhonokiol, raloxifene, and their derivatives, HU-308 and/or BCP.

Abstract: The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4?-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.

Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.

Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.

Abstract: Disclosed are compositions comprising beta-caryophyllene (BCP) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using BCP. Disclosed are also compositions comprising CB2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using CB2 receptor agonists.

Abstract: The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4?-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.

Abstract: The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4?-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.

Abstract: The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4?-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.

Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.

Abstract: Disclosed are compositions comprising beta-caryophyllene (BCP) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using BCP. Disclosed are also compositions comprising CB2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using CB2 receptor agonists.

Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.

Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.